drugset / Trial / NCT05926492
A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.
Timeline
- Start
- 2024-01-09
- Primary completion
- 2025-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 200 mg | Oral |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 45 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 2.5 g | — |
| Comparator | Methotrexate | Small molecule | 8 g | — |
| Comparator | Methotrexate | Small molecule | 12 g | — |